AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04578041 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRPMS (Transcranial Rotating Permanent Magnet Stimulation)
Description: TRPMS ( is administered through a head cap worn by the participant and controlled by QHTimeStimulate application via computer tablet.~* Modality: Excitatory stimulation~* Frequency: 5 Hz~* Interval between stimulus: 100 ms~* Duration of each stimulus: 25 ms~* Duration of stimulation: 40 minutes~* Position of microstimulators: over primary motor cortex and supplementary motor area for Arm 1; over left and right dorsolateral prefrontal cortex for Arm 2
Study NCT04578041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Program
Description: Aerobic exercise consisting of 40 minutes of cycling training with a seated elliptical machine. The daily physical activity program will consist of three 10-minute bouts of aerobic exercise interspersed with two 5-minute bouts of rest. The participants will exercise maintaining their Heart Rate (HR) at least between 60-80% of the maximum age-related HR.
Study NCT04578041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized CT (Cognitive Training)
Description: Computerized cognitive training (CT) consisting of 40 minutes Brain-HQ training.~The adaptive cognitive training games also serve to engage them during the stimulation session, and to keep them seated at the computer for the entire duration of the session.
Study NCT06502028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngeal mask airway
Description: The airway is secured with a video laryngeal mask airway.
Study NCT06502028 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: The participant is intubated with an endotracheal tube via direct laryngoscopy.
Study NCT05559385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assissted Therapy
Description: Houston Bionics ExoRehab X brand/model device was used for improving the upper extremity in subacute stroke.
Study NCT05559385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: It is an upper extremity rehabilitation program prepared in line with individual needs.
Study NCT06462586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily
Study NCT06462586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally, once daily
Study NCT04743856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAT
Description: Participants will receive a physical activity tracker and encouragement to increase activity.
Study NCT04908449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectus sheath block with bupivacaine
Description: Rectus sheath block with local anesthetic versus sham block with saline
Study NCT04908449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rectus sheath block with bupivacaine
Description: Rectus sheath block with local anesthetic versus sham block with saline
Study NCT05091112 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal surgery
Description: In participants who undergo elective lumbar spinal surgery and consented for research, the medial branch and dorsal rami will be harvested for histological analysis.
Study NCT05091112 — intervention group
Intervention type: OTHER
Intervention: Histology
Description: The harvested nerves will be fixed, cut into smaller sections. Analysis of macroscopic and light microscopic sections will be carried out
Study NCT05047913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FTX
Description: Given By IV
Study NCT06168019 — intervention group
Intervention type: OTHER
Intervention: Exposures
Description: COVID-19, Influenza and ORV impact on the pregnant woman, her fetus and newborn
Study NCT06652529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AROG4-01
Description: AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.
Study NCT06652529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AROG4-01
Description: AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.~This study is an open label, Phase 1 dose escalation trial with two expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 8 to 20 patients in total will be enrolled in part A, covering up to 6 dose levels.~* Part B: At the dose expansion phase, AROG4-01 two cohorts of ten patients with advanced solid tumor each will be recruited. One cohort of patients with advanced MPM (cohort 1) and a second cohort of patients with other solid tumors (cohort 2).
Study NCT06670365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat acclimation by warm-water immersion
Description: Participants will be immersed in a whirlpool tub to the shoulder level in a circulated water bath maintained at \~40°C until their core temperature achieves a steady-state of 38.5°C for 60 minutes. The warm-water immersion protocol will be repeated for 6 more consecutive days.
Study NCT06597916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arexvy powder and suspension for injection
Description: Arexvy powder and suspension for injection (RSV vaccine)
Study NCT06597916 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Arexvy powder and suspension for injection
Description: Arexvy powder and suspension for injection (RSV vaccine)
Study NCT06617026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: a topical rectal ointment. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
Study NCT06617026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azadirachtin
Description: a topical oil. The patients are instructed to apply it twice a day, using a gloved finger, inside the anal canal and the perianal region for 40 days
Study NCT06617026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fissurectomy and lateral sphincterectomy
Description: fissurectomy and lateral sphincterectomy
Study NCT06681883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action group
Description: A nursing care program based on the Model of Modifiable Factors Specific to Problematic Internet Use in Adolescents (MFPA)~The nursing care program based on the MFPA model is designed for adolescents with problematic internet use. The program is grounded in the concepts of the draft model. It consists of eight sessions, each expected to last 40-50 minutes. One session will be held per week. The first session includes introductions and an overview of the program, the second session aims to strengthen the adolescent's motivation for change, the third session focuses on improving the adolescent's self-control skills, the fourth session aims to enhance family functionality, the fifth session helps develop offline activities to replace internet use, the sixth and seventh sessions work on developing coping skills, and the eighth session includes the evaluation and termination of the program.
Study NCT06681168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagal nerve stimulation
Description: Participants will be randomly assigned to receive either taVNS applied to the tragus of the ear or a sham stimulation from the time of randomization for 90 days.~Active simulations will be carried out daily using the Parasym device for 60 minutes twice daily during the acute phase (two sessions, one in the morning and one in the afternoon), and once daily (single session) during the rehabilitation phase. The stimulation waveform includes trains of pulses with widths of 200 µs and repetition rate of 20 Hz (Nurosym proprietary waveform); current delivery will be set at a predefined therapeutic level below 0.25 W/cm² (Watts per centimeter squared), that being the defined risk threshold for a thermal burn. The device adjusts stimulation intensity at 0.8 mA steps; the starting intensity will be set at 16 mA (level 20).
Study NCT06681168 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The sham stimulation involves placing the electrode on the same site without delivering any electrical current. The device will be applied to the tragus without electrical current delivered from the time of randomization for 90 days (i.e., the time of randomization coincides with the first stimulation session).
Study NCT05024773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Description: Schedule: once a week for 12 consecutive weeks (induction phase). Patients who achieve a complete response at the end of the induction phase will enter the maintenance phase, during which ONCOFID-P-B is administered once a month for 12 months until recurrence or progression of the disease.
Study NCT05730699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: divozilimab
Description: anti-CD20 monoclonal antibody
Study NCT06595121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: Budesonide 1 mg/2mL nebuliser suspension
Study NCT06595121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: Pulmicort(r) 1 mg/2mL nebuliser suspension
Study NCT06306274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus (0,1%) ointment
Study NCT06595121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: suspension of 10g activated charcoal slurried in 70mL of water
Study NCT06680635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavonoid-enriched juice and a low-calorie diet
Description: Orange juice enriched in flavonoids (14%: nobiletin, sinensetin, tangeretin) (200 ml/day) and low calorie diet
Study NCT05314387 — intervention group
Intervention type: DEVICE
Intervention: SMR TT Hybrid Glenoid without Cementless Finned Short Stem
Description: The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.
Study NCT05314387 — intervention group
Intervention type: DEVICE
Intervention: SMR TT Hybrid Glenoid with Cementless Finned Short Stem
Description: The subject SMR Hybrid Glenoid System and SMR cementless finned short stem is intended for both primary or revision anatomic and reverse shoulder joint replacement. The glenoid components when used as part of an anatomic shoulder replacement are intended for cemented fixation.~The fins are intended to enhance press-fit fixation. The same proximal morse taper is used for coupling to the same humeral bodies in the SMR Shoulder System. The SMR finned short stem is intended for cementless fixation.
Study NCT06306274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment
Study NCT06680635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Food supplement: placebo juice and a low calorie diet
Description: Placebo juice (200 ml/day) and a low calorie diet
Study NCT06681038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses.
Study NCT06681038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Intravenous doublet chemotherapy FOLFIRI or FOLFIRINOX + targeted systemic therapy (anti-EGFR or anti-VEGF).~Administered every 2 weeks for 12 cycles. Dosage and administration at recommended doses.
Study NCT06681038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: In addition to standard systemic treatment, patients receive also four PIPAC procedures with pressurized aerosol containing oxaliplatin.~The PIPAC procedure is repeated up to a maximum of 4 times every 6 weeks.
Study NCT06680700 — intervention group
Intervention type: DEVICE
Intervention: Perin Health Patch
Description: The Perin Health Patch (PHP) is a non-invasive, chest-worn device designed to monitor blood oxygen saturation (SpO2) and additional vital signs, including heart rate, respiratory rate, ECG, and bioimpedance (BioZ). Unlike traditional fingertip pulse oximeters, the PHP integrates multi-wavelength photoplethysmography (PPG) sensors with ECG and BioZ technology, allowing for continuous SpO2 tracking even during movement and daily activities.
Study NCT06681285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab ;Anlotinib
Description: Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Study NCT06681311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: During the research period, all participants will undergo swimming training for 1 hour per day, 3-4 days a week for 6 weeks. The control group will perform a 5-minute land warm-up covering traditional shoulder, torso, and leg areas before their routine swimming training. In addition to the traditional warm-up program and swimming training, the experimental group will also participate in core and shoulder stabilization exercises under the supervision of a physiotherapist.
Study NCT06154525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RO water
Description: Aquafina's reverse osmosis (RO) water, produced by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively. The RO water ampoules are produced using a similar process as the LIVESPO Preg-Mom/ KIDS but contain 5ml of high-quality RO water from Aquafina (proper noun)
Study NCT06117397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: A text messaging intervention that includes enhanced content such as tailoring, video links and a chat function
Study NCT06154525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LiveSpo Preg-Mom
Description: LiveSpo® Preg-Mom has a registration number 7695/2020/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
Study NCT06154525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LiveSpo KIDS
Description: LiveSpo® KIDS has a registration number 1537/2023/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam.
Study NCT06681376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort menu and cart
Description: The comfort menu and cart will be implemented after the pre-intervention data collection phase is completed. The menu will list the items available on the cart and will be presented to eligible patients in printed or digital format (on a tablet). The cart will be placed in an easily accessible area within the ED. Approximated retail prices have been previously reported.~Comfort Cart Contents:~* Hot and cold packs;~* Extra blanket and pillow;~* Face towel;~* Gloves and hat;~* Personal hygiene kit;~* Items for distraction;~* Items to enhance communication.~Comfort Menu Options:~* Physiotherapy assessment;~* Conversation with chaplain, concierge, or social worker;~* List of resources for older adults needing community services;~* Home care assistance.
Study NCT04558593 — intervention group
Intervention type: PROCEDURE
Intervention: Active surveillance
Description: Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)
Study NCT04558593 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Per standard of care: partial or full resection of the kidney, imaging annually
Study NCT05181033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Letrozole
Description: Patient will receive letrozole 2.5mg daily plus lenvatinib 14mg daily until disease progression/unacceptable toxicity.~Patient review, safety evaluations, thyroid function monitoring and urine dipstick will be done. Toxicities will be graded using NCI CTCAE toxicity grading vs 4.0. Patient should be discontinued if drug cannot be resumed within 28 days due to toxicities.~Drugs should be withheld when subject has imminent risk to develop hypertensive crisis/has significant risk factors for severe complications of uncontrolled hypertension. Drugs can be resumed once patient received same hypertensive medications for at least 48 hours and the BP is controlled.~Lenvatinib should be withheld for at least 1 week prior to elective surgery, at least 2 weeks after major surgery, until adequate wound healing.~For risk of ONJ, oral dental examination and preventive dentistry should be considered prior to lenvatinib intake.~There is no dose modifications for letrozole.
Study NCT05181033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Patients will be treated with Fulvestrant 500mg injections that are administered into the muscles (intramuscularly). This is injected at 2-weekly interval for the first 3 doses, followed by 4-weekly interval dosing.
Study NCT05333328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression with endocrine treatments
Description: * Ovarian function suppression (OFS) with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.~* Either goserelin acetate or leuprorelin Acetate is allowed.~* These patients are able to choose bilateral salpingo-oophorectomy instead of OFS.~* Chemotherapy is omitted in these patients.
Study NCT04710134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reslizumab
Description: Reslizumab 3,4, or 5 mg/kg IV q4 weeks
Study NCT06629246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional heart failure treatment
Description: Conventional heart failure treatment, which may include pharmacological therapies such as diuretics, ACE inhibitors/ARBs, beta-blockers, or aldosterone receptor antagonists, based on the clinical requirements of the condition.
Study NCT06629246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pogejiuxin decoction combined with conventional heart failure treatment
Description: In addition to receiving standard heart failure treatment, patients are also administered Pogejiuxin Decoction.The formula of Pogejiuxin Decoction is as follows : Processed Aconite 60g (decocted initially for 1 hour), Dried Ginger 60g, Honey-fried Licorice 60g, Cornus officinalis 60g, Ginseng 30g (decocted separately), Raw Dragon Bone 30g (decocted initially for 1 hour), Raw Oyster Shell 30g (decocted initially for 1 hour), Living Magnetite 30g, for a total of 7 prescriptions. Usage: Uniformly decocted with a herbal medicine decoction machine to obtain the medicinal liquid, one prescription per day, taken twice daily in the morning and evening, each time 100ml, for a continuous treatment of 7 days.
Study NCT06494826 — intervention group
Intervention type: OTHER
Intervention: colonoscopy procedure
Description: Candidates for a medically-indicated colonoscopy due to suspected new-onset CD or non-specific GI complaints or routine screening for colorectal cancer as part of primary prevention.~colonoscopy will not be done for research purposes only .
Study NCT06370325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VPOD Wireless Tens Unit
Description: The VPOD unit will deliver NMES to participants in the Intervention Group.
Study NCT06370325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy as per standard of care.
Study NCT06558539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Tibial Nerve Stimulation(TTNS)
Description: Participants in this group will discontinue all relevant medications (e.g., β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs) at least 14 days before signing the informed consent and will not use these medications during the study period. They will receive treatment solely with wearable transcutaneous tibial nerve stimulation.
Study NCT06558539 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: Participants in this group will continue their prescribed medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration unchanged throughout the study. In addition to the standard medication therapy, participants will receive wearable transcutaneous tibial nerve stimulation using a wearable device
Study NCT06558539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication Therapy
Description: Participants in this group will maintain their usual medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration remaining consistent throughout the study. No additional interventions will be provided.
Study NCT06283524 — intervention group
Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study NCT06211517 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews with visual mediations
Description: Semi-structured interviews with visual mediations / An hour-long interview
Study NCT06211517 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured interviews
Study NCT06370325 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy as per standard of care.
Study NCT06305403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum creatinin level
Description: Serum creatinine and urine amounts will be checked for five days.